Annex VI to Regulation (EC) No 1272/2008 is amended as follows:
in Part 1, the heading of point 1.1.1.4 is replaced by the following:
‘Chemical name’;
in Part 3, Table 3.1 is amended as follows:
the title of the second column is replaced by the following: ‘Chemical name’;
the title of the penultimate column is replaced by the following: ‘Specific Conc. Limits, M-factors and ATEs (*)
(*) ATEs for oral and dermal exposure routes are expressed in mg/kg bw, which stands for milligram per kilogram bodyweight.’;
the entry corresponding to index number 607-414-00-6 is deleted;
the entries corresponding to index numbers 006-044-00-7, 015-101-00-5, 016-096-00-2, 017-011-00-1, 025-002-00-9, 603-180-00-4, 604-014-00-3, 604-016-00-4, 604-090-00-8, 605-003-00-6, 606-047-009, 607-096-00-9, 607-103-00-5, 607-113-00-X, 607-373-00-4, 613-167-00-5, 613-205-00-0 and 614-001-00-4 are replaced by the following entries respectively:
Index No | Chemical name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors and ATEs | Notes
Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s)
‘006-044-00-7 |
isoproturon (ISO);
3-(4-isopropylphenyl)-1,1-dimethylurea
251-835-4 | 34123-59-6 |
Carc. 2
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1
H351
H373 (blood)
H400
H410
GHS08
GHS09
Wng
H351
H373 (blood)
H410
M = 10
M = 10’
‘015-101-00-5 |
phosmet (ISO);
S-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl] O,O-dimethyl phosphorodithioate;
O,O-dimethyl-S-phthalimidomethyl phosphorodithioate
211-987-4 | 732-11-6 |
Repr. 2
Acute Tox. 4
Acute Tox. 3
STOT SE 1
Aquatic Acute 1
Aquatic Chronic 1
H361f
H332
H301
H370 (nervous system)
H400
H410
GHS08
GHS06
GHS09
Dgr
H361f
H332
H301
H370 (nervous system)
H410
M = 100
M = 100’
‘016-096-00-2 |
thifensulfuron-methyl (ISO);
methyl 3-(4-methoxy-6-methyl-1,3,5-triazin-2-ylcarbamoylsulfamoyl)thiophene-2-carboxylate
| 79277-27-3 |
Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410 | |
M = 100
M = 100’
‘017-011-00-1 | sodium hypochlorite, solution … % Cl active | 231-668-3 | 7681-52-9 |
Skin Corr. 1B
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
H314
H318
H400
H410
GHS05
GHS09
Dgr
H314
H410
EUH031 |
M = 10
M = 1
EUH031:
C ≥ 5 %
B’
‘025-002-00-9 | potassium permanganate | 231-760-3 | 7722-64-7 |
Ox. Sol. 2
Repr. 2
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1
H272
H361d
H302
H400
H410
GHS03
GHS08
GHS07
GHS09
Dgr
H272
H361d
H302
H410’
‘603-180-00-4 |
colecalciferol;
cholecalciferol;
vitamin D3
200-673-2 | 67-97-0 |
Acute Tox. 2 Acute Tox. 2 Acute Tox. 2
STOT RE 1
H330
H310
H300
H372
GHS06
GHS08
Dgr
H330
H310
H300
H372
inhalation:
ATE = 0,05 mg/L (dusts or mists)
dermal:
ATE = 50 mg/kg bw
oral:
ATE = 35 mg/kg bw
STOT RE 1; H372: C ≥ 3 %
STOT RE 2; H373: 0,3 % ≤ C < 3 %’
‘604-014-00-3 |
chlorocresol;
4-chloro-m-cresol;
4-chloro-3-methylphenol
200-431-6 | 59-50-7 |
Acute Tox. 4
Skin Corr. 1C
Eye Dam. 1
STOT SE 3
Skin Sens. 1B Aquatic Acute 1
Aquatic Chronic 3
H302
H314
H318
H335
H317
H400
H412
GHS07
GHS05
GHS09
Dgr
H302
H314
H335
H317
H410
M = 1’ |
‘604-016-00-4 |
1,2-dihydroxybenzene;
pyrocatechol
204-427-5 | 120-80-9 |
Carc. 1Β
Muta. 2
Acute Tox. 3
Acute Tox. 3
Skin Irrit. 2
Eye Irrit. 2
H350
H341
H311
H301
H315
H319
GHS08
GHS06
Dgr
H350
H341
H311
H301
H315
H319
oral:
ATE = 300 mg/kg bw
dermal:
ATE = 600 mg/kg bw’
‘604-090-00-8 | 4-tert-butylphenol | 202-679-0 | 98-54-4 |
Repr. 2
Skin Irrit. 2
Eye Dam. 1
Aquatic Chronic 1
H361f
H315
H318
H410
GHS08
GHS05
GHS09
Dgr
H361f
H315
H318
H410
M = 1’ |
‘605-003-00-6 |
acetaldehyde;
ethanal
200-836-8 | 75-07-0 |
Flam. Liq. 1
Carc. 1B
Muta. 2
STOT SE 3
Eye Irrit. 2
H224
H350
H341
H335
H319
GHS02
GHS08
GHS07
Dgr
H224
H350
H341
H335
H319’
‘606-047-00-9 | 2-benzyl-2-dimethylamino-4′-morpholinobutyrophenone | 404-360-3 | 119313-12-1 |
Repr. 1B
Aquatic Acute 1
Aquatic Chronic 1
H360D
H400
H410
GHS08
GHS09
Dgr
H360D
H410’
‘607-096-00-9 | maleic anhydride | 203-571-6 | 108-31-6 |
Acute Tox. 4
STOT RE 1
Skin Corr. 1B
Eye Dam. 1
Resp. Sens. 1
Skin Sens. 1A
H302
H372 (respiratory system) (inhalation)
H314
H318
H334
H317
GHS07
GHS08
GHS05
Dgr
H302
H372 (respiratory system) (inhalation)
H314
H334
H317
EUH071 | Skin Sens. 1A; H317: C ≥ 0,001 %’ |
‘607-103-00-5 | succinic anhydride | 203-570-0 | 108-30-5 |
Acute Tox. 4
Skin Corr. 1
Eye Dam. 1
Resp. Sens. 1
Skin Sens. 1
H302
H314
H318
H334
H317
GHS07
GHS05
GHS08
Dgr
H302
H314
H334
H317
EUH071’ | |
‘607-113-00-X | isobutyl methacrylate | 202-613-0 | 97-86-9 |
Flam. Liq. 3
STOT SE 3
Skin Irrit. 2
Skin Sens. 1B
H226
H335
H315
H317
GHS02
GHS07
Wng
H226
H335
H315
H317
D’
‘607-373-00-4 | quizalofop-P-tefuryl (ISO); (+/–) tetrahydrofurfuryl (R)-2-[4-(6-chloroquinoxalin-2-yloxy)phenyloxy]propionate | 414-200-4 | 200509-41-7 |
Carc. 2
Repr. 2
Acute Tox. 4
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1
H351
H361fd
H302
H373
H400
H410
GHS08
GHS07
GHS09
Wng
H351
H361fd
H302
H373
H410
M = 1
M = 1’
‘613-167-00-5 | reaction mass of 5-chloro-2-methyl-2H-isothiazol-3-one and 2-methyl-2H-isothiazol-3-one (3:1) | — | 55965-84-9 |
Acute Tox. 2
Acute Tox. 2
Acute Tox. 3
Skin Corr. 1C
Eye Dam. 1
Skin Sens. 1A Aquatic Acute 1
Aquatic Chronic 1
H330
H310
H301
H314
H318
H317
H400
H410
GHS06
GHS05
GHS09
Dgr
H330
H310
H301
H314
H317
H410
EUH071 |
Skin Corr. 1C; H314: C ≥ 0,6 %
Skin Irrit. 2; H315: 0,06 % ≤ C < 0,6 %
Eye Dam. 1; H318: C ≥ 0,6 %
Eye Irrit. 2; H319: 0,06 % ≤ C < 0,6 %
Skin Sens. 1A; H317: C ≥ 0,0015 %
M = 100
M = 100
B’
‘613-205-00-0 | propiconazole (ISO); (2RS,4RS;2RS,4SR)-1-{[2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-yl]methyl}-1H-1,2,4-triazole | 262-104-4 | 60207-90-1 |
Repr. 1B
Acute Tox. 4
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H360D
H302
H317
H400
H410
GHS08
GHS07
GHS09
Dgr
H360D
H302
H317
H410
M = 1
M = 1’
‘614-001-00-4 |
nicotine (ISO);
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
200-193-3 | 54-11-5 |
Acute Tox. 2
Acute Tox. 2
Acute Tox. 2
Aquatic Chronic 2
H330
H310
H300
H411
GHS06
GHS09
Dgr
H330
H310
H300
H411
inhalation:
ATE = 0,19 mg/L (dusts or mists)
dermal:
ATE = 70 mg/kg bw
oral:
ATE = 5 mg/kg bw’
the following entries are inserted in the appropriate places, following the order of the entries set out in Table 3.1:
Index No | Chemical name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors and ATEs | Notes
Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s)
‘604-094-00-X |
isoeugenol; [1]
(E)-2-methoxy-4-(prop-1-enyl)phenol; [2]
(Z)-2-methoxy-4-(prop-1-enyl)phenol [3]
202-590-7 [1]
227-678-2 [2]
227-633-7 [3]
97-54-1 [1]
5932-68-3 [2]
5912-86-7 [3]
Skin Sens. 1A | H317 |
GHS07
Wng
H317 | | Skin Sens. 1A; H317: C ≥ 0,01 %’ |
‘607-724-00-1 | 2,3,5,6-tetrafluoro-4-(methoxymethyl)benzyl (1R,3R)-2,2-dimethyl-3-[(1Z)-prop-1-en-1-yl]cyclopropanecarboxylate; epsilon-metofluthrin | — | 240494-71-7 |
Acute Tox. 4
Acute Tox. 3
STOT SE 1
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1
H332
H301
H370 (nervous system)
H373
H400
H410
GHS06
GHS08
GHS09
Dgr
H332
H301
H370 (nervous system)
H373
H410
M = 100
M = 100’
‘607-725-00-7 | isopropyl (2E,4E,7S)-11-methoxy-3,7,11-trimethyldodeca-2,4-dienoate; S-methoprene | — | 65733-16-6 |
Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410 | |
M = 1
M = 1’
‘607-726-00-2 |
pinoxaden (ISO);
8-(2,6-diethyl-4-methylphenyl)-7-oxo-1,2,4,5-tetrahydro-7H-pyrazolo[1,2-d][1,4,5]oxadiazepin-9-yl 2,2-dimethylpropanoate
| 243973-20-8 |
Repr. 2
Acute Tox. 4
Acute Tox. 4
Eye Irrit. 2
STOT SE 3
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 3
H361d
H332
H302
H319
H335
H317
H400
H412
GHS08
GHS07
GHS09
Wng
H361d
H332
H302
H319
H335
H317
H410
inhalation:
ATE = 4,63 mg/L (dusts or mists)
oral:
ATE = 500 mg/kg bw
M = 1’
‘607-727-00-8 |
tetramethrin (ISO);
(1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl)methyl 2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropanecarboxylate
231-711-6 | 7696-12-0 |
Carc. 2
Acute Tox. 4
STOT SE 2
Aquatic Acute 1
Aquatic Chronic 1
H351
H302
H371 (nervous system) (inhalation)
H400
H410
GHS08
GHS07
GHS09
Wng
H351
H302
H371 (nervous system) (inhalation)
H410
M = 100
M = 100’
‘607-728-00-3 | (1,3,4,5,6,7-hexahydro-1,3-dioxo-2H-isoindol-2-yl)methyl (1R-trans)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate | 214-619-0 | 1166-46-7 |
Carc. 2
Acute Tox. 4
STOT SE 2
Aquatic Acute 1
Aquatic Chronic 1
H351
H302
H371 (nervous system) (inhalation)
H400
H410
GHS08
GHS07
GHS09
Wng
H351
H302
H371 (nervous system) (inhalation)
H410
M = 100
M = 100’
‘607-729-00-9 |
mesosulfuron-methyl (ISO);
methyl 2-[(4,6-dimethoxypyrimidin-2-ylcarbamoyl)sulfamoyl]-α-(methanesulfonamido)-p-toluate;
| 208465-21-8 |
Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410 | |
M = 100
M = 100’
‘607-730-00-4 |
spirodiclofen (ISO);
3-(2,4-dichlorophenyl)-2-oxo-1-oxaspiro[4.5]dec-3-en-4-yl 2,2-dimethylbutyrate
| 148477-71-8 |
Carc. 1B
Repr. 2
STOT RE 2
Skin Sens. 1B
Aquatic Chronic 1
H350
H361f
H373
H317
H410
GHS08
GHS07
GHS09
Dgr
H350
H361f
H373
H317
H410
M = 10’ |
‘607-731-00-X | sodium methyl [(4-aminophenyl)sulphonyl]carbamate; sodium methyl (EZ)-sulfanilylcarbonimidate; asulam-sodium | 218-953-8 | 2302-17-2 |
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H317
H400
H410
GHS07
GHS09
Wng
H317
H410
M = 1
M = 1’
‘607-732-00-5 | salicylic acid | 200-712-3 | 69-72-7 |
Repr. 2
Acute Tox. 4
Eye Dam. 1
H361d
H302
H318
GHS08
GHS07
GHS05
Dgr
H361d
H302
H318’
‘608-068-00-9 |
flutianil (ISO);
(2Z)-{[2-fluoro-5-(trifluoromethyl)phenyl]thio}[3-(2-methoxyphenyl)-1,3-thiazolidin-2-ylidene]acetonitrile
| 958647-10-4 | Aquatic Chronic 1 | H410 |
GHS09
Wng
H410 | | M = 100’ |
‘612-293-00-8 | reaction mass of 1-[2-(2-aminobutoxy)ethoxy]but-2-ylamine and 1-({[2-(2-aminobutoxy)ethoxy]methyl}propoxy)but-2-ylamine | 447-920-2 | - |
Repr. 2
Acute Tox. 4
Skin Corr. 1B
Eye Dam. 1
H361f
H302
H314
H318
GHS08
GHS07
GHS05
Dgr
H361f
H302
H314
EUH071’ | |
‘613-326-00-9 | 2-methylisothiazol-3(2H)-one | 220-239-6 | 2682-20-4 |
Acute Tox. 2
Acute Tox. 3
Acute Tox. 3
Skin Corr. 1B
Eye Dam. 1
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 1
H330
H311
H301
H314
H318
H317
H400
H410
GHS05
GHS06
GHS09
Dgr
H330
H311
H301
H314
H317
H410
EUH071 |
Skin Sens. 1A; H317: C ≥ 0,0015 %
M = 10
M = 1’
‘613-327-00-4 |
pyroxsulam (ISO);
N-(5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-2-methoxy-4-(trifluoromethyl)pyridine-3-sulfonamide
| 422556-08-9 |
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H317
H400
H410
GHS07
GHS09
Wng
H317
H410
M = 100
M = 100’
‘613-328-00-X | 1-vinylimidazole | 214-012-0 | 1072-63-5 | Repr. 1B | H360D |
GHS08
Dgr
H360D | | Repr. 1B; H360D: C ≥ 0,03 %’ |
‘616-224-00-2 |
amisulbrom (ISO);
3-(3-bromo-6-fluoro-2-methylindol-1-ylsulfonyl)-N,N-dimethyl-1H-1,2,4-triazole-1-sulfonamide
| 348635-87-0 |
Carc. 2
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1
H351
H319
H400
H410
GHS08
GHS07
GHS09
Wng
H351
H319
H410
M = 10
M = 10’